Egypt vs Syrian Arab Republic: Access to anti-retroviral drugs, female
Egypt
46.0%
in 2024
Syrian Arab Republic
41.0%
in 2024
Egypt rank
125th
Syrian Arab Republic rank
127th
Access to anti-retroviral drugs, female over time
- Egypt
- Syrian Arab Republic
How they compare
Egypt currently reports 46.0% against 41.0% in Syrian Arab Republic, a difference of 5.0%.
That makes Egypt's figure about 1.1 times Syrian Arab Republic's.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Syrian Arab Republic ahead.
Egypt ranks 125th and Syrian Arab Republic ranks 127th of 141 countries.
Syrian Arab Republic has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Egypt | Syrian Arab Republic | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.1% | 5.4% | 5.3% | Syrian Arab Republic |
| 2010s | 14.0% | 26.9% | 12.9% | Syrian Arab Republic |
| 2020s | 36.8% | 41.4% | 4.6% | Syrian Arab Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Egypt or Syrian Arab Republic?
- Egypt, at 46.0% against 41.0% in Syrian Arab Republic as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Egypt and Syrian Arab Republic?
- 5.0%, with Egypt ahead.
- How many years of comparable data are there for Egypt and Syrian Arab Republic?
- 25 years are reported by both, from 2000 to 2024.
- How do Egypt and Syrian Arab Republic rank globally for access to anti-retroviral drugs, female?
- Egypt ranks 125th and Syrian Arab Republic ranks 127th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.